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Abstract
Purpose This review describes the evidence base that has helped define the role of decompressive craniectomy (DC) in the
management of patients with traumatic brain injury (TBI).
Recent Findings The publication of two randomized trials (DECRA and RESCUEicp) has strengthened the evidence base. The
DECRA trial showed that neuroprotective bifrontal DC for moderate intracranial hypertension is not helpful, whereas the
RESCUEicp trial found that last-tier DC for severe and refractory intracranial hypertension can significantly reduce the mortality
rate but is associated with a higher rate of disability. These findings have reopened the debate about (1) the indications for DC in
various TBI subtypes, (2) alternative techniques (e.g., hinge craniotomy), (3) optimal time and material for cranial reconstruction,
and (4) the role of shared decision-making in TBI care. Additionally, the role of primary DC when evacuating an acute subdural
hematoma is currently undergoing evaluation in the context of the RESCUE-ASDH randomized trial.
Summary This review provides an overview of the current evidence base, discusses its limitations, and presents a global
perspective on the role of DC, as there is growing recognition that attention should also focus on low- and middle-income
countries due to their much greater TBI burden.
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Introduction
Traumatic brain injury (TBI) remains a major public health
problem worldwide. It is a leading cause of mortality and dis-
ability across the globe, with low- and middle-income countries
(LMICs) facing the greatest disease burden [1•]. Brain swelling
and intracranial hypertension are well-recognized secondary in-
sults associated with increased mortality and poorer outcomes.
Decompressive craniectomy (DC) refers to the practice of
removing a large bone flap and opening the underlying dura in
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order to control brain swelling and raised intracranial pressure
(ICP). This review aims to present the evidence base
concerning the role of DC following TBI, to identify areas
of uncertainty, and to discuss future directions.
Historical Perspectives
There is evidence that the practice of trephination (a word
coming from Ancient Greek trypanon: to drill) dates back to
around 10,000 B.C. [2]. The first known written report
concerning the use of trephination dates back to Ancient
Greece, more precisely to Hippocrates, who defined the indi-
cations for trephination in relation to different types of skull
fractures [2, 3]. The practice of trephination continued during
the Roman era, Middle Ages, and Renaissance. One physician
whose work was particularly significant was Berengario da
Carpi (1466–1530). He provided the first classification of
head trauma and its outcome in relation to surgical techniques
[4].
In the modern era, Theodor Kocher first described the ne-
cessity of opening the skull in the presence of increased intra-
cranial pressure: Bif there is no cerebrospinal fluid (CSF) pres-
sure, but brain pressure exists, then pressure relief must be
achieved by opening the skull^ [5]. The first results of
Kocher’s doctrine were published by Harvey Cushing in
1908, who reported a drastic reduction in TBI mortality from
50 to 15% after subtemporal DC [6]. During the twentieth
century, different DC techniques were described
(hemicraniectomy, circumferential, bifrontal), but lack of con-
sensus about indications and significant variation in outcomes
paved the way for randomized trials in the beginning of the
twenty-first century [7, 8].
Definitions
Hemicraniectomy, also known as unilateral DC or
frontotemporoparietal craniectomy, refers to the removal of a
large frontotemporoparietal bone flap, whereas bifrontal DC
refers to the removal of a bone flap extending from the floor of
the anterior cranial fossa to the coronal suture, and to the
middle cranial fossa floor bilaterally.Wide opening of the dura
is a necessary part of the procedure.
Subtypes of TBI in Which DC Is Used
& A DC is most frequently undertaken in comatose patients
with an acute subdural hematoma (ASDH) and associated
brain swelling in the early phase after injury [9–11]. In this
group of patients, the ASDH is evacuated and a large bone
flap is left out either because the brain is bulging beyond
the inner table of the skull or because increasing brain
swelling (e.g., in a patient with large cerebral contusions)
is anticipated in the postoperative period. This type of DC
is termed primary and is most frequently a unilateral
hemicraniectomy. With regard to timing from injury, a
primary DC is usually undertaken within the first 24 h,
but in some papers the time window extends to the first
48–72 h [12•, 13].
& A DC can also be undertaken in comatose patients who
have parenchymal hemorrhage or contusions (usually
frontotemporal) with substantial mass effect. This usually
manifests as midline shift (> 5 mm) and/or uncal hernia-
tion in the case of predominantly unilateral contusions or
obliterated basal cisterns in the case of bilateral contu-
sions. Such patients may initially receive ICP monitoring
(if available) and proceed to a DC later if their ICP be-
comes difficult to control. This type of DC is termed sec-
ondary and can be unilateral (for predominantly unilateral
pathology) or bifrontal (for predominantly bilateral pa-
thology). Alternatively, patients with severe mass effect
and clinical signs of herniation (such as anisocoria) may
receive a DC early after injury without prior monitoring of
ICP, especially in areas with low availability of
neuromonitoring resources [14, 15•].
& Patients who have had a craniotomy (i.e., bone flap re-
placed at end of procedure) for evacuation of an intracra-
nial hematoma in the early phase after injury occasionally
undergo a subsequent DC if their ICP becomes difficult to
control or if they deteriorate neurologically with radiolog-
ical evidence of increasing mass effect. This usually oc-
curs in patients in whom coexisting contusions are
blossoming.
& Less frequent indications include closed TBI with diffuse
brain swelling without any significant hematomas/contu-
sions, gunshot wound with gross hemorrhage and swell-
ing; and severe blast injury with gross swelling [16–18].
Overall, primary DC at the same time as evacuation of a
hematoma is the most frequent scenario for performance of
DC [19•]. Secondary DC undertaken after a period of ICP
monitoring in order to control refractory elevation of ICP
and/or to treat clinical or radiological deterioration is a less
frequent indication.
Strengthening the Evidence Base
In the 1990s, after advances in imaging, prehospital, and in-
tensive care led to improvements in TBI management, the
importance of developing the evidence base for DC by
conducting robust studies became apparent.
It is widely accepted that well-planned experimental stud-
ies can provide robust evidence to inform clinical practice.
Curr Trauma Rep (2018) 4:326–332 327
When one is interested in evaluating the effectiveness of a
treatment, a control group, ideally in the context of a random-
ized controlled trial (RCT), is necessary. Through random
assignment of individuals, the treatment and control groups
are likely to be balanced in both observable and non-
observable characteristics. Consequently, we can be fairly
confident that any differences in outcome between the two
groups are due to the experimental effect of exposure to the
treatment [20].
However, RCTs may not always be feasible for practical or
ethical reasons. Additionally, treatments with dramatic effects
that are unlikely to have resulted from inadequately controlled
biases do not need to be subjected to a RCT. Such an example
from the field of TBI would be evacuation of a substantial
extradural hematoma in a patient who is neurologically com-
promised. Furthermore, a number of potential difficulties,
such as lack of clinical equipoise, strong patient and clinician
preferences, imbalance in surgical expertise, cross-over be-
tween groups, and difficulty with blinding, may render surgi-
cal trials particularly challenging [21].
New approaches, such as comparative effectiveness re-
search (CER), have become popular in recent years. Non-
experimental CER studies—such as the CENTER-TBI pro-
ject (https://www.center-tbi.eu/)—aim to utilize heterogeneity
in care provision and outcomes to compare the effectiveness
of treatments that are standard practice in some centers but not
in others. Nevertheless, the methodology of non-experimental
CER studies and interpretation of their findings remain a work
in progress. Therefore, even though these efforts are important
and promising, they can only be seen as being complementary
to randomized trials. Pragmatic RCTs, which compare two or
more treatments in the Breal world,^ are a form of CER, the
so-called experimental CER [22]. Although RCTs and non-
experimental CER are both important facets of TBI research,
only RCTs are widely accepted as the gold-standard method
for assessing the efficacy and effectiveness of therapeutic in-
terventions. Hence, if a question is sufficiently refined to al-
low the design of an RCT, such a study should be undertaken
whenever feasible [23].
Overview of Main Randomized Trials RCT
in TBI
The main randomized trials in the field of DC following TBI
are three in number: (1) DECRA trial, which examined the
role of neuroprotective, secondary, and bifrontal DC for mod-
erate intracranial hypertension; (2) RESCUEicp trial, which
examined the role of last-tier secondary DC for severe and
refractory intracranial hypertension; and (3) RESCUE-
ASDH trial, which is examining the role of primary DC for
ASDH.
The DECRA trial, for which results were published in
2011, enrolled 155 patients with severe diffuse TBI and mod-
erate intracranial hypertension in three different countries
(Australia, New Zealand, and Saudi Arabia) [24••]. Patients
were eligible for randomization within the first 72 h after
trauma if the ICP was higher than 20 mmHg for > 15 min
(continuously or intermittently) within a 1-h period and was
not responding to first-tier ICP-lowering interventions.
Patients were randomized to bifrontal DC or to continuing
medical care. The primary endpoint was the extended
Glasgow Outcome Scale (GOSE) score at 6 months. The mor-
tality was similar in both groups (19% vs 18%), but more
surgical patients had an unfavorable GOSE (70% vs 51%;
p = 0.02). Following post hoc adjustment for pupil reactivity
at baseline, the rate of unfavorable outcome was no longer
significantly different between the two arms (adjusted OR
1.90; 95% CI 0.95–3.79). Although DECRA has been widely
criticized for various reasons [25], we view it as a valuable
trial that addressed a very specific question. On the basis of its
findings, we are able to conclude that bifrontal DC should not
be used as a neuroprotective measure for moderate posttrau-
matic intracranial hypertension in well-resourced settings.
The RESCUEicp trial, for which results were published
in 2016, enrolled 408 patients with severe and refractory
posttraumatic intracranial hypertension in 20 countries
[26••]. Patients were eligible for randomization at any time
point after trauma if the ICPwas higher than 25mmHg for at
least 1 h and did not respond to first-tier and second-tier
ICP-lowering interventions. Patients were randomized to
secondary DC (bifrontal DC or hemicraniectomy) or stan-
dardized medical therapy (with the option of barbiturates
after randomization). The primary endpoint was GOSE
score at 6 months. DC resulted in substantially lower mor-
tality (26.9% vs 48.9%) but higher rates of vegetative state
(8.5% vs 2.1%), lower severe disability (21.9% vs 14.4%),
and upper severe disability (independent at home; 15.4% vs
8%) than medical care. The rates of moderate disability and
good recovery were similar in the two groups. Nevertheless,
surgical patients continued improving beyond the 6 months,
and at 12 months, 45.4% of surgical patients had a favorable
outcome (upper severe disability or better) compared to
32.4% in the medical group (p = 0.01). These results sug-
gest that secondary DC can be helpful as a last-tier interven-
tion to reduce mortality in the subset of TBI patients with
severe and refractory posttraumatic intracranial hyperten-
sion. However, caution is needed because approximately
40% of extra survivors generated by DC will be dependent
on others at 12 months. The contrasting results of DECRA
and RESCUEicp arise from differences in study hypothe-
ses, eligibility criteria, and therapeutic protocols; the main
differences have been summarized in Table 1 [27].
The RESCUE-ASDH trial is currently ongoing. This trial
aims to address the paucity of high-quality evidence regarding
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the best surgical strategy (primary DC or craniotomy) for pa-
tients with ASDH (Table 2). A previously published survey
has shown that a higher percentage of neurosurgeons from
other European countries (48/110; 44%) as compared with
UK/Irish neurosurgeons (29/138; 21%) use primary DC in
more than half of ASDH cases (p < 0.001) [28]. A more recent
survey of 60 neurosurgeons from the Netherlands and
Belgium demonstrated a large variation in the decision to
combine ASDH evacuation with a DC [29•]. These results
demonstrate that a considerable lack of consensus exists on
the indications for primary DC in this context. The RESCUE-
ASDH trial was funded by the UK National Institute for
Health Research (NIHR) and was launched in 2014 with the
aim of comparing primary DC (bone flap left out) with crani-
otomy (bone flap replaced and fixed) for patients with a seri-
ous TBI undergoing evacuation of an ASDH. Similar to real-
world practice, eligible patients are randomized intraopera-
tively after evacuation of their ASDH. Patients with signifi-
cant brain swelling preventing safe replacement of the bone
flap are not suitable for randomization and are being enrolled
in a parallel observational cohort. The study is ongoing, and
more than 400 patients have been enrolled in the randomized
trial from 35 sites worldwide [23].
Finally, another study that should be mentioned is a ran-
domized trial that took place in five centers in China to com-
pare outcomes after a standard-sized trauma DC (12 × 15-cm
flap) vs a limited DC (6 × 8-cm flap) in severe TBI patients
with refractory intracranial hypertension [30•]. The authors
recruited 486 patients in total and found that the mortality rate
was lower (26% vs 35%) and favorable outcome rate higher
(39.8% vs 28.6%) after standard trauma DC compared to lim-
ited DC (p < 0.05).
Table 1 Differences between DECRA and RESCUEicp trials
DECRA RESCUEicp
Recruitment up to 72 h post-TBI 100% of patients 56% of patients
TBI type Diffuse injury only Diffuse injury and/or mass lesions
(including contusions and evacuated hematomas)
ICP threshold > 20 mmHg for 15 min in 1 h > 25 mmHg for at least 1 h
ICP-lowering therapies before randomization Tier 1 Tiers 1 and 2
Pooled mortality 18.7% 37.5%
Mortality in DC vs medical group 19 vs 18% 26.9 vs 48.9%
Documented follow-up 6 months 6 and 12 months
Table 2 Inclusion, exclusion criteria, and outcome measures of RESCUE-ASDH
Inclusion criteria 1. Adult head-injured patients (> 16 years)
2. ASDH on CT
3. The admitting neurosurgeon feels that the hematoma needs to be evacuated with a large bone flap (≥ 11-cm anteroposterior
diameter) either by a craniotomy or decompressive craniectomy (patients with additional lesions such as intracerebral
hemorrhage/contusions) may be included
Exclusion criteria 1. Bilateral ASDHs both requiring evacuation
2. Previous enrollment in RESCUE-ASDH study
3. Severe pre-existing physical or mental disability or severe co-morbidity which would lead to a poor outcome even if the
patient made a full recovery from the head injury
Primary outcome
measure
Extended Glasgow Outcome Scale (GOSE) at 12 months
Secondary outcome
measures
1. GOSE at 6 months
2. Quality of life (EQ-5D) at discharge from neurosurgical ward, 6 and 12 months
3. Glasgow Coma Scale (GCS) on discharge from the intensive care unit (ICU) and from neurosurgical ward
4. Length of stay in ICU, neurosurgical and rehabilitation unit
5. Discharge destination from neurosurgical ward
6. Mortality
7. Serious adverse events and surgical complications
8. Subsequent readmissions within the 1-year follow-up period
9. Return to operating theater for cranial surgery within 2 weeks after randomization
10. Hydrocephalus requiring shunt insertion within the 12 months follow-up period
11. Therapy intensity level in the ICU
12. Economic evaluation
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Limitations of Current Evidence Base
About 90% of worldwide trauma-related deaths occur in
LMICs. However, less than 10% of the RESCUEicp patient
population was enrolled in LMICs (36/408 patients from six
countries), whereas all patients in the DECRA study were
from high-income countries (HICs). This fact raises some im-
portant questions. Firstly, is it possible to extrapolate the re-
sults from studies taking place in HICs (where prehospital,
acute neurosurgical, and postacute care are generally delivered
in a more systematic way) to the results that can be expected in
LMICs? Secondly, is it possible for neurosurgeons working in
LMICs to follow recommendations derived from the DECRA
and RESCUEicp studies, given that ICP monitoring may not
be available in their daily practices? Nevertheless, the burden
of TBI is much higher in LMICs, and patients are being treat-
ed for TBI despite the absence of evidence directly applicable
to these countries. These are issues that are receiving further
study as part of efforts to improve global neurotrauma care.
Such an initiative is the NIHR Global Health Research Group
on Neurotrauma, which is supported by the World Federation
of Neurosurgical Societies. This international group aims to
improve neurotrauma care in LMICs.
Additionally, more attention needs to be paid to the issue of
cranial reconstruction (cranioplasty) following DC.
Neurological dysfunction associated with large skull defects
has been proposed as an important factor that can influence
the outcome of patients after DC [31•, 32]. Small, uncon-
trolled studies suggest that earlier cranioplasty (within three
months of DC) may facilitate rehabilitation and may even
independently improve long-term outcome [33••]. From the
surgical viewpoint, the tissue planes seem to be more favor-
able when a cranioplasty is undertaken early. However, due to
a longstanding belief that the rate of infection may be higher
with earlier cranioplasty, many of these operations are under-
taken in a delayed fashion. This is clearly an important area for
future research. Additionally, despite the plethora of different
materials available for cranioplasty following DC (e.g., titani-
um, PEEK, hydroxyapatite, and the patient’s own bone flap),
uncertainty remains as to whether anyone of them is associat-
ed with better outcomes [34]. Cranioplasty-related costs differ
among various materials, which is an important consideration
for LMICs as well as several HICs with state-funded
healthcare systems.
Another area of debate is the use of floating or hinged bone
flaps as a potential decompressive method for TBI. Floating or
hinged bone flaps have the potential to control at least mod-
erate swelling while at the same time obviating the need for a
subsequent cranioplasty [35, 36•]. This is an important con-
sideration in resource-limited settings. These techniques could
be evaluated prospectively in randomized controlled studies,
as if they are proven to be beneficial, they could advance the
care of patients in LMICs.
The opening of basal cisterns (cisternostomy) has also been
suggested as a surgical maneuver for managing posttraumatic
brain swelling and elevated ICP [37]. However, this technique
requires a microscope and instruments for microneurosurgery,
which may limit its utility in resource-constrained settings.
Additionally, the fact that an external cisternal drain is left in
situ (with CSF drainage of 150–200 ml/day for 6 days in a
recent case report) [38] suggests that the therapeutic effect of
cisternostomy may be mediated at least in part by CSF drain-
age. A much simpler and faster method for achieving CSF
drainage is an external ventricular drain (ventriculostomy),
but due to the additional hypothesized benefits of
cisternostomy, it has become clear that the only way to deter-
mine the utility of cisternostomy is through the conduct of
randomized trials. Despite the criticism that is often directed
to randomized surgical trials, they remain the optimal study
design for rigorous evaluation of surgical interventions, tech-
niques, and devices [39, 40].
Finally, it should be emphasized that the perspectives of
patients and their families should always be considered when
determining the degree of Bacceptable^ disability.
Additionally, the degree of Bacceptable^ disability varies from
person to person and is dependent on many factors, such as
culture, social environment, and religion. Therefore, the indi-
rect input of the patient (as best as is possible) and of families
is very important when determining the degree of acceptable
disability for an individual, and consequently whether a DC
should be considered [41, 42].
Conclusions
Several TBI subtypes associated with brain swelling and/or
raised ICP can bemanaged byDC. However, current evidence
from multicenter clinical trials suggests that (1) early neuro-
protective bifrontal DC for mild to moderate intracranial hy-
pertension is not superior to medical management for patients
with diffuse TBI, and (2) unilateral or bifrontal DC used as a
last-tier therapy for patients with severe, sustained, and refrac-
tory posttraumatic intracranial hypertension leads to a sub-
stantial mortality reduction but increases disability (both lower
and upper severe disability) compared to medical manage-
ment. The RESCUE-ASDH trial is currently open and aims
to define the role of primary DC for patients with acute sub-
dural hematomas and swelling. The global neurosurgical com-
munity needs to consider the roles of DC, cranioplasty, and
other decompressive procedures (such as floating or hinge
craniotomy) not just in HICs but also, and perhaps more im-
portantly, in LMICs due to their much greater TBI burden.
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